These findings highlight the pivotal role of microglia in GBM pathogenesis, suggesting that targeting TREM2, CX3CR1, and CSF1R may offer novel strategies to counteract microglia-driven immune suppression and enhance anti-tumor immunity. This evidence concerns the gene CSF1R and glioblastoma.